Sleep-time blood pressure (BP) is a stronger risk factor for cardiovascular disease (CVD) events than awake and 24 h BP means, but the potential role of asleep BP as therapeutic target for diminishing CVD risk is uncertain. We investigated whether CVD risk reduction is most associated with progressive decrease of either office or ambulatory awake or asleep BP mean. 
Introduction
Specific features of the 24 h blood pressure (BP) pattern determined by ambulatory blood pressure (ABP) monitoring (ABPM) have been explored as biomarkers or mediators of target tissue injury and triggers of and risk factors for cardiovascular disease (CVD) events. 1 Various independent prospective investigations and meta-analyses demonstrate the ABPM-derived asleep BP mean is a stronger risk factor for CVD events than the awake and 24 h BP means or daytime office blood pressure measurements (OBPM). [2] [3] [4] [5] [6] [7] On the basis of the substantial evidence documenting ABP is a marker of long-term CVD outcomes independently of OBPM, 2,5-8 several international guidelines and recommendations now propose ABPM as requirement to confirm the diagnosis of adult hypertension. 9, 10 All previous studies addressing the merit of ABPM vs. OBPM as risk factor or even predictor for CVD events, except the Monitorización Ambulatoria para Predicción de Eventos Cardiovasculares Study (MAPEC, Ambulatory Blood Pressure Monitoring for Prediction of Cardiovascular Events), 5, 11 relied solely upon a single, low-reproducible 12 24 h ABPM evaluation per participant. This approach is unsound because it presumes all features of the baseline-determined ABP pattern are maintained without alteration throughout the many years of follow-up despite institution or modification of BP-lowering therapy, aging, and development of target organ damage and concomitant morbidity. Additionally, lack of systematic and multiple ABPM evaluations of participants over time in all previously reported long-term follow-up studies, except MAPEC, precluded exploration of the potential relationship between modification of specific ABP parameters by hypertension therapy and reduction of CVD risk. Incorporation of periodic, at least annual, ABPM patient assessment during follow-up in the single-centre MAPEC Study first established therapeutic reduction of the asleep BP mean and enhancement of the sleep-time relative BP decline towards the normal dipper BP pattern lessen CVD risk, 5 results yet awaiting validation particularly in the routine primary care clinical setting. The Hygia Project is a research network established to extend the use of ABPM in primary care to diagnose hypertension, evaluate response to treatment, and assess patient CVD and other risks. 13 Among the multiple ongoing ABPM-based studies within the network, we here report the findings on two of the main objectives of the Hygia Project, namely to: (i) compare the potential incremental value of multiple ABPM-derived parameters with OBPM as risk markers of CVD morbidity and mortality and (ii) most important from the therapeutic point of view, prospectively investigate whether specific treatment-induced changes in ABPM-derived parameters, primarily the progressive decrease in asleep BP mean, reduce CVD risk.
Methods

Inclusion and exclusion criteria
The prospective multicentre Hygia Project was approved by the state Ethics Committee of Clinical Research. Details of the study design, management, investigators' training, quality control, safety and compliance assessment, clinical and ABPM procedures, sample size calculations, followup, and all other relevant methodological aspects of the Hygia Project are extensively described elsewhere. 13 Presently, the Hygia Project is composed of 40 clinical sites (primary care centres) within the Galician Social Security Health Service [Servicio Galego de Saúde (SERGAS), Northern Spain] involving 292 investigators properly trained to ABPM and all study procedures. The sample for testing the two specific hypotheses stated above represents a population of Spanish men and women > _18 years of age, adhering to a routine of daytime activity and night-time sleep, referred for ABPM mainly to confirm/refute the diagnosis of hypertension inferred by daytime OBPM of untreated individuals or to evaluate BP control in treated hypertensive persons, and who provided written informed consent for inclusion. Exclusion criteria were pregnancy, history of drug/ alcohol abuse, night/shift-work employment, acquired immunodeficiency syndrome, secondary hypertension, CVD disorders (unstable angina pectoris, heart failure, life-threatening arrhythmia, atrial fibrillation, kidney failure, and Grade III-IV retinopathy), intolerance to ABPM, and inability to communicate and comply with all study requirements. For the present study, the targeted median follow-up was 5 years, with an a priori required > _1-year minimal follow-up per participant. 13 Participants, treatment, and diagnostic criteria
Between 2008 and 2015, we recruited 18 731 persons who fulfilled the inclusion/exclusion criteria, with 18 158 providing all required information for study. The other 573 individuals were excluded due to inadequate ABPM sampling at baseline and non-consent for follow-up ABPM evaluations. Additionally, 80 participants were excluded due to lack of the required 1-year minimum follow-up. Thus, the final evaluated population for the hypotheses tested herein is 18 078 persons [9769 men/8309 women; 59.1 ± 14.3 (mean ± standard deviation (SD)) years of age]. Hypertension was defined according to current ABPM criteria: awake systolic blood pressure (SBP)/diastolic blood pressure (DBP) mean > _135/85 mmHg, or asleep SBP/DBP mean > _120/70 mmHg, or BPlowering treatment. 14, 15 According to these ABPM criteria, 15 674 participants were hypertensive at the time of recruitment (9709 untreated) and assigned, as previously described, 13 either to ingest the entire dose of at least one BP-lowering medication (ARB, ACEI, CCB, ß-blocker, and/or diuretic) at bedtime (and the remaining ones, if any, upon awakening) or all of them upon awakening (Supplementary material online, Table S1 ). Participating physicians were given the choice of prescribing any medication of their choice from any of the five listed recommended therapeutic classes as first-line therapy in untreated participants and combination therapy for uncontrolled individuals. If, based on the ABPM threshold criteria provided above, the ABP of a given patient remained uncontrolled at any time during follow-up when treated with medication(s) at the maximum recommended dose(s), additional therapy could be added in keeping with current clinical practice guidelines. 15 Diabetes was defined as fasting glucose > _126 mg/dL on at least two clinical assessments > _3 months apart in participants without prior history of diabetes, or glucose-lowering treatment. 16 Diagnosis of metabolic syndrome was established by the National Cholesterol Education Program Adult Treatment Panel III (ATP-III) revised definition. 17 Chronic kidney disease (CKD) was defined as either estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 , albuminuria (albumin/creatinine ratio > _30 mg/gCr), or both, on at least two occasions > _3 months apart. 18 eGFR (mL/min/1.73 m 2 ) was estimated by the CKD-EPI equation. 19 Diagnosis of obstructive sleep apnoea (apnoea/hypopnoea index > _10) was corroborated by overnight in-hospital polysomnography when the participant reported significant daytime hypersomnia or he/she or bedmate reported loud snoring, choking, interrupted breathing, and/or multiple awakenings during night-time
Ambulatory blood pressure and other assessments
At inclusion and thereafter at every scheduled clinic visit throughout follow-up, trained investigators obtained at least three consecutive OBPM from participants using a validated automatic oscillometric device (HEM-705IT, Omron Health Care Inc., Vernon Hills, IL, USA) after resting in a seated position for > _10 min. Immediately thereafter, ABPM was instituted with a properly calibrated and validated SpaceLabs 90207 device (SpaceLabs Inc., Issaquah, WA, USA) to measure SBP, DBP, and heart rate every 20 min between 07:00 and 23:00 h and every 30 min during the night for 48 consecutive hours. The BP cuff was always worn on the nondominant arm. Upper arm circumference was measured at each study visit to ensure proper cuff size for OBPM and ABP assessment. The monitoring period was 48 h, instead of the most usual 24 h, to optimize reproducibility of results, as accurate calculation of ABP characteristics (including mean BP values), and dipping classification depends markedly on ABPM duration. 12 Individuals were instructed to adhere to their usual activities with minimal restrictions, but to avoid daytime napping and maintain a similar activity-rest schedule during the two consecutive days of monitoring. Participants kept a diary to list, among other information, time of retiring to bed at night, awakening in the morning, consumption of meals, and ingestion of medications. Such individualized information was used to derive the awake and asleep BP means of each person. In keeping with current recommendations, 14 BP series were considered invalid for analysis, and thus requiring repeated ABPM, if > _30% of the measurements were missing, data were lacking for an interval of >2 h, data were obtained when the rest-activity schedule was irregular or inconsistent during the 2 days of monitoring, or the sleep span was <6 h or >12 h. Blood and urine samples were obtained at every clinic visit for ABPM evaluation. Participants arrived to the clinical centre between 08:00 and 09:00 h, after overnight fasting, for blood withdrawal from an antecubital vein. Blood and urine samples were analysed using routine automatic techniques at the corresponding laboratory facility of the SERGAS, all complying with the same quality standards.
Follow-up
Identical above-described evaluation procedures were scheduled annually, or more frequently in uncontrolled hypertensive participants and those affected by compelling clinical conditions associated with increased CVD risk-including diabetes, CKD, and past CVD events. 13 Investigators, mainly those of the Hygia Project Scientific Committee, reviewed the complete electronic clinical records of every enrolled participant at least annually and at least 1 year following each person's last ABPM evaluation. Categorization of CVD and other events listed in the electronic clinical records was accomplished by previously defined diagnostic criteria at the corresponding referring tertiary hospital services and by external non-investigator medical specialists. 13 The Hygia Project Events Committee, composed of independent clinicians blinded to medical records, ABPM findings, and treatment scheme of those with hypertension, periodically and collegiately evaluated such clinical reports, dissociated from the participant's identification, to ascertain and certify every documented event. Registered events include: death from all causes, myocardial infarction, angina pectoris, coronary revascularization, heart failure, lower extremities acute arterial occlusion, retinal artery thrombotic occlusion, haemorrhagic stroke, ischaemic stroke, and transient ischaemic attack. The a priori defined primary vascular study endpoint is CVD outcome (composite of CVD death, myocardial infarction, coronary revascularization, heart failure, ischaemic stroke, and haemorrhagic stroke). Cardiovascular disease risk was evaluated on the basis of the: (i) baseline ABPM evaluation per participant, as customary in all previous ABPM reports [2] [3] [4] [5] [6] [7] ; (ii) final ABPM evaluation, i.e. that just before (usually <1 year) each documented event or last ABPM evaluation in non-event cases; and (iii) decrease from baseline during follow-up in OBPM and all potentially relevant ABPM-derived parameters.
Demographic and clinical characteristics were compared among groups of participants who did and did not experience an event by t-test (quantitative variables) or non-parametric v 2 test (proportions). The
Cox proportional-hazard model, adjusted for significant confounding variables, served to estimate hazard ratios (HR) and 95% CI for events per tested potential prognostic BP parameter as well as their combinations. We standardized these HR by expressing them in terms of 1-SD increments of the BP parameter. All demographic, anthropometric, and clinical laboratory variables of Table 1 were tested as potential confounding variables by non-automatic (forward and backward) stepwise Cox survival analysis. Adjustments were finally applied for the jointly significant influential characteristics of age, sex, type 2 diabetes, CKD, cigarette smoking, high-density lipoprotein (HDL)-cholesterol, hypertension treatmenttime (either all BP-lowering medications upon awakening vs. the daily dosing of at least one medication at bedtime), and history of previous CVD event, as they were the only ones consistently significant in the tested Cox regression models. On the other hand, the impact of BP reduction during follow-up on CVD risk was evaluated by entering the decrease from baseline in the analysed BP parameter at each subsequent ABPM evaluation as a time-dependent covariate in the Cox regression analysis, thus allowing also proper confirmation of the underlying hypotheses for the analysis. For survival analysis, follow-up was established as the time-interval from the date of the analysed ABPM assessment to either the date of the confirmed event or that of the last clinical evaluation in non-event participants.
We additionally compared the discriminative and predictive added value of the different tested ABPM parameters to OBPM by the C statistic (area under the receiver operating characteristic curve) 20 and Akaike
Information Criterion (AIC). 21 Model selection was performed by evalu-
ating differences in AIC between tested ABPM parameters according to the rules proposed by Burnham & Anderson. 22 Lack of significant collinearity between the asleep BP mean and all other tested OBPM and ABP parameters was ascertained by calculating tolerance coefficients and corresponding variance inflation factors. Statistical analyses were performed using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA) and R version 3.3.3 (R Foundation for Statistical Computing). Table 1) . In addition, at baseline they had greater OBPM SBP and PP (but lower OBPM DBP), plus laboratory findings of higher glucose, creatinine, uric acid, and urinary albumin/creatinine ratio, but lower eGFR and HDL-cholesterol ( Table 1) . At baseline, the 48 h mean of SBP was significantly greater and that of DBP significantly lower among event-subjects ( Table 1 ). The largest difference between the event and non-event cohorts was in the asleep SBP mean. Moreover, the sleep-time relative SBP decline was significantly lower (P < 0.001) and prevalence of non-dipping significantly higher, 66 vs. 44%, among eventsubjects (P < 0.001; Table 1 ). All differences between groups reported in Table 1 with a P-value <0.001 would remain significant after correction for multiple testing.
Office blood pressure measurement and ambulatory blood pressure monitoringderived characteristics as markers of cardiovascular disease risk Table S1 ). OBPM, average ABP values, and prevalence of nondipping at baseline were also not significantly different between groups (Supplementary material online, Table S1 ). There were no differences at the end of the study in the classes and number of hypertension medications (usually at maximum doses) prescribed for therapy between patients of the two treatment-time schemes (Supplementary material online, Table S2 ). The most frequent treatment-schemes in monotherapy were ARB or ACEI (69%) and CCB (12%); combinations of ARB/ACEI with either diuretic (43%) or CCB (26%) in double therapy; and combinations of ARB/ ACEI-diuretic with CCB (60%) or ß-blocker (28%) among patients treated with > _3 medications. Data of the last ABPM evaluation revealed significantly lower asleep, but not awake, SBP/DBP means in participants of the bedtime than morning-treatment regimen (P < 0.001; Supplementary material online, Table S2 ). The sleep-time relative SBP/DBP decline was significantly greater among those of the bedtime-treatment regimen; accordingly, the proportion of patients with the non-dipper BP pattern was significantly lower in the bedtime than the morning-treatment group (32 vs. 50%; P < 0.001). Table 2 (centre column) reports the HR of CVD based on OBPM and ABPM of the final evaluation. The findings are similar to those described above for the corresponding baseline evaluation ( Table 2 , left column), thereby providing further evidence for the greater value of the asleep BP mean and sleep-time relative BP decline compared to any of the other ABP characteristics analysed separately as potential individual markers of CVD risk ( Figure 1A) .
We next explored the potential combined contribution to CVD risk of the multiple BP parameters listed in Table 2 . When the asleep SBP mean was jointly evaluated as an additional confounding variable with either OBPM-derived SBP or any other ABPM-derived SBP parameter, only the former was a significant marker of CVD risk [1.29 (95% CI 1.22-1.35) per SD elevation in asleep SBP, P < 0.001; 1.03 (0.97-1.09) per SD elevation in OBPM SBP, P = 0.32; and 1.02 (0.94-1.10) per SD elevation in awake SBP mean, P = 0.68; Figure 1B] . The joint contribution with the asleep SBP mean to CVD risk was significant only for the diminished sleep-time relative SBP decline (P = 0.042, Figure 1B) .
To further investigate the clinical relevance of the awake and asleep BP means on CVD risk, participants were categorized for illustrative purposes into four mutually exclusive cohorts according to ABP level, i.e. normal or high awake and normal or high asleep BP mean, independent of OBPM, using established ABPM thresholds of 135/85 mmHg for awake SBP/DBP means and 120/70 mmHg for asleep SBP/DBP means.
14,15 Figure 2A indicates: (i) similar adjusted HR for CVD outcome of participants with normal asleep BP whether the awake BP mean is normal or elevated (P = 0.32); (ii) equivalent HR in hypertensive patients with high asleep BP whether the awake BP mean is normal or elevated (P = 0.47); and (iii) significantly higher adjusted HR of CVD events in participants with elevated than normal asleep BP mean, independent of the awake BP mean being below or above 135/ 85 mmHg (always P < 0.001).
Each of the four cohorts of participants categorized by awake and asleep BP means in Figure 2A were further categorized according to either normal or elevated OBPM using the most common 140/ 90 mmHg thresholds, i.e. yielding in total eight mutually exclusive cohorts. Cardiovascular disease risk was significantly higher in all of the four patient cohorts who had high asleep ABP mean, regardless of whether OBPM or awake ABP mean was normal or elevated, than in all of the other four cohorts of normal asleep ABP mean ( Figure  2B) . Additionally, there were no significant differences in HR for CVD risk of participants with normal vs. high OBPM within each of the four cohorts defined by awake and asleep BP means (always P > 0.11, Figure 2B) .
From the point of view of discrimination/prediction ability of OBPM vs. ABPM, the adjusted Cox regression model that included the asleep SBP mean had the lowest AIC among all other BP parameters tested in Table 2 . Moreover, difference in AIC with . Decrease in office blood pressure measurement and ambulatory blood pressure during follow-up as markers of reduced cardiovascular disease risk Table 2 (right column) presents the results of the time-dependent Cox regression analysis-adjusted by the significant confounders of age, sex, diabetes, CKD, cigarette smoking, HDL-cholesterol, baseline BP, hypertension treatment-time, and history of previous CVD event-based upon progressive decrease in BP during follow-up, i.e. difference between the values obtained per participant at recruitment and each ABPM determination up to his/her final evaluation. The decrease in the asleep SBP mean was the most significant marker of increased event-free survival, i.e. absence of CVD outcome [0.75 4 shows, for the studied population divided into quintiles, the relationship between CVD outcome and achieved OBPM and ABP at final evaluation, thus suggesting potential outcome-based BP therapeutic targets. For OBPM SBP, the adjusted HR was only slightly higher in the last compared to the first four quintiles. There was a slightly significant increase in CVD risk with progressively higher awake SBP mean ( Figure 4B) . In contrast, across all quintiles there was a highly significant exponential decrease in risk of CVD outcome with progressively lower achieved asleep SBP mean ( Figure 4C) . Additionally, the adjusted HR for CVD outcome increased progressively and significantly when the achieved sleep-time SBP decline was <13% ( Figure 4D) . .
Discussion
The Hygia Project is the first outcomes study conducted within primary care-based customary clinical practice to assess prospectively, in the so far largest cohort evaluated by repeated ABPM, the prognostic value for CVD morbidity and mortality not just of OBPM and ABP parameters upon recruitment but, of much more medical relevance, changes in such during sufficient duration follow-up by periodic (at least annual) highly reproducible 48 h ABPM in conjunction with recorded patient diary information, as recommended, 14, 15 of bedtime at night and awakening time in the morning to derive individualized awake and asleep BP means plus sleep-time relative BP decline. Results document daytime OBPM is neither an independent significant marker nor proper therapeutic target for reducing CVD risk when the asleep BP mean is taken into account (Figures 1-3) . Figure 2 documents the assumed merit of elevated OBPM as risk factor of CVD events derives exclusively from the risk of those individuals who additionally have elevated BP during sleep. Analyses based on the ABP profile obtained per participant both at baseline, as customary in all previous studies entailing ABPM as marker of CVD risk, [2] [3] [4] [5] [6] [7] as well as at final evaluation, usually within <1-year of every documented event, indicate the asleep SBP mean is the most significant marker of CVD outcome among the various evaluated ABP parameters ( Table 2) , both individually and jointly when combined with other potential ABP-derived risk factors in the best possible Cox proportional-hazard model ( Figure 1) . In fact, only the diminished sleep-time relative SBP decline might add prognostic value to the Cox model that already includes the asleep SBP mean and corrected for relevant confounding variables ( Figure 1B) . Moreover, when the asleep BP mean was adjusted for the OBPM or awake BP mean, only the former remained a significant predictor of CVD outcome, regardless of whether the OBPM or awake BP mean was normal or elevated ( Figures 1B and 2) . Both office and ambulatory DBP had markedly lower prognostic value than SBP ( Table 2) , in keeping with current knowledge 10, 15 and the recognized prognostic value of PP.
Relying on OBPM for diagnosing hypertension is associated with a very high 47% misclassification (Groups 2, 4, 5, and 7 from left to right in Figure 2B ), rendering OBPM no better than flipping a coin to identify individuals at elevated CVD risk and in need of therapeutic intervention.
Despite the limitations of the C-statistic to evaluate the predictive value of highly variable and modifiable factors such as BP, 20 our findings further document asleep SBP mean provides significantly stronger prediction/discrimination of CVD outcome than OBPM or any other ABPM-derived parameter. Indeed, adding OBPM or awake SBP mean to the model already including asleep SBP mean does not improves prediction of CVD outcome, while inclusion of asleep SBP mean significantly increases the prediction and discrimination provided by either OBPM or awake BP mean. Banegas et al. 24 also found significantly better prediction of CVD mortality with ABP than 24 for mortality due to ischaemic heart disease, stroke, and heart failure (jointly accounting for 80% of CVD deaths) were 1.025, 1.025, and 1.025, respectively (their Supplementary material online, Table S3 ); accordingly, the adjusted HR of awake SBP mean for total CVD mortality can hardly be the reported 1.54 , leading to the conclusion that indeed only asleep SBP mean is a significant marker of CVD mortality. And second, the HRs for OBPM and multiple ABPM-derived parameters reported by Banegas et al. 24 are fully identical for CVD mortality and total mortality; this is unsound, as CVD mortality represented 34% of total deaths and non-CVD mortality might not be associated with increased BP in many cases (including cancer, accidents, neurological conditions, etc.). In our study, also conducted in Spain and CVD mortality accounting for a similar 36% of total deaths, the adjusted HRs of OBPM, awake, and asleep SBP analysed jointly in the same Cox model were: for CVD mortality 1.07 These findings document the expected strong difference in the prognostic value of BP for CVD and non-CVD mortality, plus the highly significant value of asleep SBP mean as marker not just of CVD outcome (Figures 1-3 ) but also of CVD mortality in particular.
Most important from the perspective of prevention, evaluation of changes in ABP parameters during follow-up documents the progressive decrease in asleep SBP mean and increase in sleep-time relative SBP decline (towards the more normal dipper BP pattern) are significantly associated with reduced CVD risk (Figures 3 and 4) . As reported, the relationship between asleep SBP mean decrease and CVD outcome attenuation is significant at all levels of baseline asleep SBP mean, ranging from normotension to hypertension, suggesting benefit even below the asleep SBP/DBP means of 120/70 mmHg, the current diagnostic thresholds for sleep-time hypertension. 14, 15 Indeed, analysis of the adjusted HR for CVD outcome in terms of the achieved asleep SBP mean at the last available evaluation per participant reveals significant risk reduction even when the sleep-time SBP mean is <103 mmHg (Figure 4C ), a finding that requires further investigation specially in high-risk patients. 26 Moreover, CVD risk was also increased significantly in patients with achieved sleep-time relative SBP decline at the final evaluation <13% ( Figure 4D ). This finding suggests the sleep-time relative SBP decline, as a continuous variable, and not just the dipping classification per se usually based on an arbitrary 10% threshold value, might be used, jointly with the asleep SBP level, as novel clinical indices to assess and prevent risk for future major CVD events. The latest update of the guidelines for the clinical management of adult primary hypertension from the National Institute for Health and Clinical Excellence (NICE) 9 in Great Britain recommends ABPM be conducted to corroborate the diagnosis of hypertension in all adults with elevated OBPM. Despite available evidence, here extended and qualified, on the greater prognostic value of asleep than awake BP mean 2-7 the NICE guidelines explicitly recommend such diagnosis be based solely upon the ABPM-derived daytime SBP/ DBP means > _135/85 mmHg. 9 The recent 2015 US Preventive Services Task Force (USPSTF) report 10 concludes: (i) ABPM predicts long-term CVD outcomes independently of OBPM, and (ii) ABPM, rather than OBPM, must be considered the reference standard in primary care medicine to diagnose hypertension in adults > _18 years of age. On the basis of an exploratory meta-analysis showing no apparent difference in HR for CVD risk per 10 mmHg increase between the ABPM-derived night-time, daytime, and 24 h SBP means, a finding we believe is dubious because of methodological limitations of the reviewed investigations, 27 the USPSTF report concludes that anyone of those means might be used to corroborate the diagnosis of hypertension in adults. 10 In contradiction with the recommendations of the NICE and USPSTF reports, current guidelines of the European Society of Hypertension and European Society of Cardiology state 'it is now generally accepted that out-of-office BP is an important adjunct to conventional OBPM, but the latter currently remains the 'gold standard' for screening, diagnosis, and management of hypertension '. 15,28 The 2017 guidelines of the American College of Cardiology and the American Heart Association also rely on OBPM to define hypertension, although establishing lower values of 130/ 80 mmHg for clinic SBP/DBP as new diagnostic thresholds and therapeutic targets. 29 Using as reference the above discussed USPSTF report, 10 these guidelines state 'out-of-office measurement of BP can be helpful for confirmation and management of hypertension'. Specifically, the guidelines address the importance of identifying persons with masked normotension and masked hypertension; however, these two categories are misleadingly defined by comparing OBPM with daytime ABPM or home BP measurements, thus totally disregarding asleep BP as the strongest prognosticator of CVD risk.
Contrary to all these guidelines and recommendations, results of the prospective Hygia Project collectively indicate: (i) the asleep SBP mean is the most significant prognostic marker of CVD risk, independent of the other conventional variables here corroborated to be linked with increased CVD risk, such as elevated older age, male gender, diabetes, CKD, and history of previous CVD event 5 ; accordingly, around-the-clock ABPM to derive the asleep SBP mean should be the recommended protocol to diagnose true hypertension and properly assess CVD risk; and (ii) most important, decreasing the asleep SBP mean is significantly protective, thus constituting a novel therapeutic target for reducing CVD risk over and above targeting OBPM or awake BP mean ( Figure 3B ). Among others, the major limitations of the Hygia Project are: (i) its findings require validation and extrapolation to other ethnic groups; (ii) OBPM was obtained in the presence of the investigator and thus potentially overestimated, although this approach reflects current medical practice also utilized in most previously reported studies [2] [3] [4] [5] [6] [7] ; and (iii) with regard to the potential increase in CVD event-free survival time with progressive decrease in asleep SBP mean (Figures 3  and 4) , a confirmatory study randomizing participants to at least two different threshold goals in terms of achieved asleep SBP mean is required to properly validate our findings. Such trial, already designed, approved by the heath authorities, and registered (ClinicalTrials.gov, number NCT03457168) will be conducted with the participation of most clinical sites also involved in the Hygia Project. Yet, our study has several strengths, mainly being the only large outcomes study completely integrated into routine primary care and entailing periodic 48 h ABPM evaluation at least yearly throughout the median 5.1 years of follow-up. This unique approach, used previously only in the single-centre MAPEC study, ; and (ii) in the absence of wrist-actigraphy as measured in the participants of the MAPEC study, 5, 11 properly designed subject diary to ascertain the beginning and end of the activity and sleep spans and thus derive on an individual basis the awake and asleep SBP/DBP means, rather than relying on inaccurate daytime and night-time values calculated assuming common and arbitrary fixed clock hours as used in many previous ABPM studies. [2] [3] [4] In conclusion, according to this prospective evaluation, the asleep SBP mean, but not daytime OBPM or awake ABP mean, is the most significant BP marker of CVD outcome. This finding supports the critical importance of ABPM in routine clinical medicine, as recently concluded by the USPSTF report, 10 but more specifically to accurately detect abnormal sleep-time BP and diagnose true hypertension. More important, therapeutic targeting of elevated asleep SBP mean and diminished sleep-time relative SBP decline, usually most effectively achieved by bedtime ingestion of the full daily dose of one or more hypertension medications 11, 30 as also corroborated in this prospective investigation, is associated with significantly lower risk for CVD morbidity and mortality.
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